Medlander released a statement regarding unusual stock trading activity, clarifying that, as of the present moment, the company's brain-computer interface products are still in the research and development (R&D) phase, coupled with efforts to cultivate the market. These products have not yet achieved large-scale sales and, consequently, do not exert a significant influence on the company's financial performance. From a technological standpoint, the company is dedicated to the research, development, and commercialization of non-invasive brain-computer interface technology. This approach stands in stark contrast to the invasive technology path that is predominantly pursued internationally.
